Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Mevacor Pediatric Exclusivity To Be Revisited By FDA By July 17

Executive Summary

FDA's Pediatric Exclusivity Board is expected to reevaluate the pediatric exclusivity application for Merck's cholesterol drug Mevacor (lovastatin) by July 17.

You may also be interested in...



Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal

FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.

Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal

FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.

Merck Mevacor Pediatric Exclusivity Gets July 3 Hearing; 5 Generics Stayed

The D.C. federal court is scheduled to hear arguments on Merck's Mevacor pediatric exclusivity application July 3.

Related Content

UsernamePublicRestriction

Register

PS038150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel